Cevian Capital filed a Schedule 13D for Smith & Nephew, disclosing a stake above 13% in the London-listed medical device maker. The Swedish activist firm now holds approximately $1.48 billion worth of the company, making it one of the largest outside shareholders in a business that has underperformed peers for three consecutive years. Smith & Nephew trades at $14.87 per ADR in New York, down 19% from its 2021 peak.

The 13D filing confirms what market participants suspected since late 2024: Cevian is no longer a passive holder. The firm initially disclosed a position in Smith & Nephew in November, but crossing the 13% threshold requires formal activist intent disclosure under U.S. securities law. Cevian's portfolio typically contains six to eight concentrated positions, each above 5% of the target company, with hold periods averaging four to six years. The firm's previous medical device intervention—at Getinge AB—resulted in a 74% total return over five years and a management overhaul.

Smith & Nephew's core problem is margin compression in orthopedics, where it competes against Stryker and Zimmer Biomet with inferior scale. The company's orthopedics division generated $2.1 billion in revenue last year at 17.3% operating margin, compared to Stryker's 28.4% in the same category. Cevian's prior campaigns have focused on operational leverage—cutting overlapping R&D, consolidating manufacturing footprints, and separating underperforming divisions. Smith & Nephew's advanced wound management and sports medicine units both face reimbursement headwinds, making them potential divestiture candidates worth an estimated $3.2 billion combined.

The timing matters. Smith & Nephew appointed Deepak Nath as CEO in May 2023, giving him eighteen months to demonstrate turnaround progress before activist pressure typically escalates. The company's Q4 2024 earnings, scheduled for February 27, will show whether Nath's portfolio rationalization is yielding margin improvement or simply masking volume declines. Cevian rarely engages in public proxy fights—its model relies on private board-level negotiation—but the 13% stake provides veto power over most strategic decisions requiring shareholder approval.

Allocators should watch for three catalysts in the next six months: board composition changes, particularly the addition of medtech operational specialists; formal strategic review announcements for the wound care or sports medicine divisions; and any indication that private equity firms are conducting due diligence on carve-out opportunities. Smith & Nephew's enterprise value of $13.7 billion sits in the range where a consortium-led takeout remains plausible, though regulatory scrutiny of medtech consolidation has intensified since the Illumina-Grail disaster.

Cevian's cost of capital sits near 7.2%, meaning the firm needs Smith & Nephew to compound at roughly 12% annually to meet its return hurdles. The current consensus estimate has the company growing at 4.1% through 2026. That gap is the activist thesis.